Importer of Controlled Substances Application: Xcelience, 22519 [2018-10300]
Download as PDF
<![CDATA[
22519
Federal Register / Vol. 83, No. 94 / Tuesday, May 15, 2018 / Notices
Company
FR Docket
Patheon Pharmaceuticals, Inc ................................................................
Chattem Chemicals, Inc ..........................................................................
INSYS Manufacturing LLC ......................................................................
Siemens Healthcare Diagnostics Inc ......................................................
Cerilliant Corporation ...............................................................................
Noramco, Inc ...........................................................................................
Johnson Matthey, Inc ..............................................................................
The DEA has considered the factors in
21 U.S.C. 823(a) and determined that
the registration of these registrants to
manufacture the applicable basic classes
of controlled substances is consistent
with the public interest and with United
States obligations under international
treaties, conventions, or protocols in
effect on May 1, 1971. The DEA
investigated each of the company’s
maintenance of effective controls
against diversion by inspecting and
testing each company’s physical
security systems, verifying each
company’s compliance with state and
local laws, and reviewing each
company’s background and history.
Therefore, pursuant to 21 U.S.C.
823(a), and in accordance with 21 CFR
1301.33, the DEA has granted a
registration as a bulk manufacturer to
the above listed companies.
Dated: May 7, 2018.
John J. Martin,
Assistant Administrator.
[FR Doc. 2018–10304 Filed 5–14–18; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–392]
Importer of Controlled Substances
Application: Xcelience
ACTION:
Notice of application.
Registered bulk importers of the
affected basic classes, and applicants
therefore, may file written comments on
or objections to the issuance of the
proposed registration on or before June
14, 2018. Such persons may also file a
written request for a hearing on the
application on or before June 14, 2018.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DRW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for hearing must be
sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152. All request for hearing
daltland on DSKBBV9HB2PROD with NOTICES
DATES:
VerDate Sep<11>2014
20:27 May 14, 2018
Jkt 244001
83
83
83
83
83
83
83
FR
FR
FR
FR
FR
FR
FR
5274
5274
5810
5812
5809
5808
7221
....................................
....................................
....................................
....................................
....................................
....................................
....................................
should also be sent to: (1) Drug
Enforcement Administration, Attn:
Hearing Clerk/LJ, 8701 Morrissette
Drive, Springfield, Virginia 22152; and
(2) Drug Enforcement Administration,
Attn: DEA Federal Register
Representative/DRW, 8701 Morrissette
Drive, Springfield, Virginia 22152.
Comments and requests for hearings on
applications to import narcotic raw
material are not appropriate. 72 FR
3417, (January 25, 2007)
The
Attorney General has delegated his
authority under the Controlled
Substances Act to the Administrator of
the Drug Enforcement Administration
(DEA), 28 CFR 0.100(b). Authority to
exercise all necessary functions with
respect to the promulgation and
implementation of 21 CFR part 1301,
incident to the registration of
manufacturers, distributors, dispensers,
importers, and exporters of controlled
substances (other than final orders in
connection with suspension, denial, or
revocation of registration) has been
redelegated to the Assistant
Administrator of the DEA Diversion
Control Division (‘‘Assistant
Administrator’’) pursuant to section 7 of
28 CFR part 0, appendix to subpart R.
In accordance with 21 CFR
1301.34(a), this is notice that on April
11, 2018, Xcelience, 4901 West Grace
Street, Tampa, FL 33607 applied to be
registered as an importer of the
following basic classes of controlled
substances:
SUPPLEMENTARY INFORMATION:
Controlled
substance
Drug code
Amphetamine ...
1100
Schedule
II
The company plans to import the
listed controlled substance in finished
dosage form for clinical trials, research
and analytical purposes.
The import of this class of controlled
substance will be granted only for
analytical testing, research and clinical
trials. This authorization does not
extend to the import of a finished FDA
approved or non-approved dosage form
for commercial sale.
PO 00000
Frm 00079
Fmt 4703
Sfmt 4703
Published
February
February
February
February
February
February
February
6, 2018.
6, 2018.
9, 2018.
9, 2018.
9, 2018.
9, 2018.
20, 2018.
Dated: April 25, 2018.
Susan A. Gibson,
Deputy Assistant Administrator.
[FR Doc. 2018–10300 Filed 5–14–18; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
[OMB Number 1110–0064]
Agency Information Collection
Activities; Proposed eCollection
eComments Requested; Extension,
Without Change, of a Currently
Approved Collection; FBI
Expungement Form (FD–1114)
Criminal Justice Information
Services Division, Federal Bureau of
Investigation, Department of Justice.
ACTION: 60-Day notice.
AGENCY:
The Department of Justice
(DOJ), Federal Bureau of Investigation
(FBI), Criminal Justice Information
Services (CJIS) Division, will be
submitting the following information
collection request to the Office of
Management and Budget (OMB) for
review and approval in accordance with
the Paperwork Reduction Act of 1995.
The proposed information collection is
published to obtain comments from the
public and affected agencies.
DATES: Comments are encouraged and
will be accepted for 60 days until July
16, 2018.
FOR FURTHER INFORMATION CONTACT:
If you have additional comments
especially on the estimated public
burden or associated response time,
suggestions, or need a copy of the
proposed information collection
instrument with instructions or
additional information, please contact
Gerry Lynn Brovey, Supervisory
Information Liaison Specialist, FBI,
CJIS, Resources Management Section,
Administrative Unit, Module C–2, 1000
Custer Hollow Road, Clarksburg, West
Virginia, 26306 (facsimile: 304–625–
5093) or email glbrovey@ic.fbi.gov.
Written comments and/or suggestions
can also be sent to the Office of
Management and Budget, Office of
Information and Regulatory Affairs,
Attention Department of Justice Desk
Officer, Washington, DC 20503.
SUMMARY:
E:\FR\FM\15MYN1.SGM
15MYN1
]]>Agencies
[Federal Register Volume 83, Number 94 (Tuesday, May 15, 2018)]
[Notices]
[Page 22519]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-10300]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-392]
Importer of Controlled Substances Application: Xcelience
ACTION: Notice of application.
-----------------------------------------------------------------------
DATES: Registered bulk importers of the affected basic classes, and
applicants therefore, may file written comments on or objections to the
issuance of the proposed registration on or before June 14, 2018. Such
persons may also file a written request for a hearing on the
application on or before June 14, 2018.
ADDRESSES: Written comments should be sent to: Drug Enforcement
Administration, Attention: DEA Federal Register Representative/DRW,
8701 Morrissette Drive, Springfield, Virginia 22152. All requests for
hearing must be sent to: Drug Enforcement Administration, Attn:
Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All
request for hearing should also be sent to: (1) Drug Enforcement
Administration, Attn: Hearing Clerk/LJ, 8701 Morrissette Drive,
Springfield, Virginia 22152; and (2) Drug Enforcement Administration,
Attn: DEA Federal Register Representative/DRW, 8701 Morrissette Drive,
Springfield, Virginia 22152. Comments and requests for hearings on
applications to import narcotic raw material are not appropriate. 72 FR
3417, (January 25, 2007)
SUPPLEMENTARY INFORMATION: The Attorney General has delegated his
authority under the Controlled Substances Act to the Administrator of
the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority
to exercise all necessary functions with respect to the promulgation
and implementation of 21 CFR part 1301, incident to the registration of
manufacturers, distributors, dispensers, importers, and exporters of
controlled substances (other than final orders in connection with
suspension, denial, or revocation of registration) has been redelegated
to the Assistant Administrator of the DEA Diversion Control Division
(``Assistant Administrator'') pursuant to section 7 of 28 CFR part 0,
appendix to subpart R.
In accordance with 21 CFR 1301.34(a), this is notice that on April
11, 2018, Xcelience, 4901 West Grace Street, Tampa, FL 33607 applied to
be registered as an importer of the following basic classes of
controlled substances:
------------------------------------------------------------------------
Controlled substance Drug code Schedule
------------------------------------------------------------------------
Amphetamine........................ 1100 II
------------------------------------------------------------------------
The company plans to import the listed controlled substance in
finished dosage form for clinical trials, research and analytical
purposes.
The import of this class of controlled substance will be granted
only for analytical testing, research and clinical trials. This
authorization does not extend to the import of a finished FDA approved
or non-approved dosage form for commercial sale.
Dated: April 25, 2018.
Susan A. Gibson,
Deputy Assistant Administrator.
[FR Doc. 2018-10300 Filed 5-14-18; 8:45 am]
BILLING CODE 4410-09-P
